IP Library › Granted Patent US 10,577,627
Granted Patent B2
US 10,577,627 · App. 15/317,448 · Granted Mar 3, 2020

Chimeric capsids

Inventors: Robert Kotin (Boston, MA); Jinzhao Hou (Belmont, MA); James McLaughlin (Cambridge, MA)
Assignee: Voyager Therapeutics, Inc.
C12N15/86C07K14/005C12N2750/14122C12N2750/14143C12N2750/14145
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,577,627
App. No.
15/317,448
Granted
Mar 3, 2020
Kind
B2
Abstract

The present invention relates to viral vectors and methods of their production and use.

Claims (28)

1. An adeno-associated virus (AAV) particle comprising a capsid protein, said capsid protein comprising a chimeric polypeptide which has at least 95% identity with a reference sequence comprising SEQ ID NO: 435; wherein the chimeric polypeptide is a substitutional variant of SEQ ID NO: 435; and wherein the chimeric polypeptide comprises one or more donor sequences, said one or more donor sequences selected from SEQ ID NOs: 465, 467-470, 548-553, and fragments of at least 4 amino acids thereof.

2. The AAV particle of claim 1 , wherein said one or more donor sequences are selected from SEQ ID NOs: 469, 552, and fragments of at least 4 amino acids thereof.

3. The AAV particle of claim 1 , wherein said one or more donor sequences are selected from SEQ ID NOs: 470, 548, and fragments of at least 4 amino acids thereof.

4. The AAV particle of claim 1 , wherein said one or more donor sequences are selected from SEQ ID NO: 550, and fragments of at least 4 amino acids thereof.

5. The AAV particle of claim 1 , wherein said one or more donor sequences are selected from SEQ ID NO: 549, and fragments of at least 4 amino acids thereof.

6. The AAV particle of claim 1 , comprising a vector genome which comprises at least one payload region, wherein said payload region encodes a therapeutic protein for treatment of a neurological disease, disorder, and/or condition.

7. The AAV particle of claim 1 , comprising a vector genome which comprises at least one payload region, wherein said payload region encodes an siRNA, an shRNA, a miRNA, or a precursor thereof.

8. The AAV particle of claim 7 , wherein said payload region encodes an siRNA or a precursor thereof.

9. The AAV particle of claim 7 , wherein said payload region encodes an miRNA or a precursor thereof.

10. The AAV particle of claim 1 , wherein said one or more donor sequences are selected from SEQ ID NO: 553, and fragments of at least 4 amino acids thereof.

11. The AAV particle of claim 1 , wherein said one or more donor sequences are selected from SEQ ID NO: 467, and fragments of at least 4 amino acids thereof.

12. The AAV particle of claim 1 , wherein said one or more donor sequences are selected from SEQ ID NOs: 468, and fragments of at least 4 amino acids thereof.

13. The AAV particle of claim 1 , wherein said one or more donor sequences are selected from SEQ ID NOs: 465, and fragments of at least 4 amino acids thereof.

14. The AAV particle of claim 1 , wherein said one or more donor sequences are selected from SEQ ID NOs: 551, and fragments of at least 4 amino acids thereof.

15. The AAV particle of claim 1 , wherein said chimeric polypeptide has at least 97% identity with the reference sequence comprising SEQ ID NO: 435.

16. The AAV particle of claim 1 , wherein said chimeric polypeptide has at least 99% identity with the reference sequence comprising SEQ ID NO: 435.

17. An adeno-associated virus (AAV) capsid protein, said AAV capsid protein comprising a chimeric polypeptide which has at least 95% identity with a reference sequence comprising SEQ ID NO: 435; wherein the chimeric polypeptide is a substitutional variant of SEQ ID NO: 435; and wherein the chimeric polypeptide comprises one or more donor sequences selected from SEQ ID NOs: 465, 467-470, 548-553, and fragments of at least 4 amino acids thereof.

18. The AAV capsid protein of claim 17 , wherein said one or more donor sequences are selected from SEQ ID NO: 465 and fragments of at least 4 amino acids thereof.

19. The AAV capsid protein of claim 17 , wherein said one or more donor sequences are selected from SEQ ID NO: 467 and fragments of at least 4 amino acids thereof.

20. The AAV capsid protein of claim 17 , wherein said one or more donor sequences are selected from SEQ ID NO: 468 and fragments of at least 4 amino acids thereof.

21. The AAV capsid protein of claim 17 , wherein said one or more donor sequences are selected from SEQ ID NOs: 469, 552, and fragments of at least 4 amino acids thereof.

22. The AAV capsid protein of claim 17 , wherein said one or more donor sequences are selected from SEQ ID NOs: 470, 548, and fragments of at least 4 amino acids thereof.

23. The AAV capsid protein of claim 17 , wherein said one or more donor sequences are selected from SEQ ID NO: 549 and fragments of at least 4 amino acids thereof.

24. The AAV capsid protein of claim 17 , wherein said one or more donor sequences are selected from SEQ ID NO: 550 and fragments of at least 4 amino acids thereof.

25. The AAV capsid protein of claim 17 , wherein said one or more donor sequences are selected from SEQ ID NO: 551 and fragments of at least 4 amino acids thereof.

26. The AAV capsid protein of claim 17 , wherein said one or more donor sequences are selected from SEQ ID NO: 553 and fragments of at least 4 amino acids thereof.

27. The AAV capsid protein of claim 17 , wherein said chimeric polypeptide has at least 97% identity with the reference sequence comprising SEQ ID NO: 435.

28. The AAV capsid protein of claim 17 , wherein said chimeric polypeptide has at least 99% identity with the reference sequence comprising SEQ ID NO: 435.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2016
From: KOTIN, ROBERT; HOU, JINZHAO; MCLAUGHLIN, JAMES
To: VOYAGER THERAPEUTICS, INC.
Reel/Frame 040723/0293 →
Continuity (3)
Provisional Application 62009430 · Jun 9, 2014
Provisional Application 62009435 · Jun 9, 2014
Related Publication 20170130245A1 · May 11, 2017
Cited By (1)
US 12,398,181